BR112018001275A2 - métodos para tratar transtornos associados à angiogênese e neovascularização - Google Patents

métodos para tratar transtornos associados à angiogênese e neovascularização

Info

Publication number
BR112018001275A2
BR112018001275A2 BR112018001275A BR112018001275A BR112018001275A2 BR 112018001275 A2 BR112018001275 A2 BR 112018001275A2 BR 112018001275 A BR112018001275 A BR 112018001275A BR 112018001275 A BR112018001275 A BR 112018001275A BR 112018001275 A2 BR112018001275 A2 BR 112018001275A2
Authority
BR
Brazil
Prior art keywords
methods
dimer
patient
neovascularization
angiogenesis
Prior art date
Application number
BR112018001275A
Other languages
English (en)
Portuguese (pt)
Inventor
Burian Gabriela
Dornbush Kirk
Greene William
Original Assignee
Iconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Inc filed Critical Iconic Therapeutics Inc
Publication of BR112018001275A2 publication Critical patent/BR112018001275A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112018001275A 2015-07-22 2016-07-22 métodos para tratar transtornos associados à angiogênese e neovascularização BR112018001275A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195709P 2015-07-22 2015-07-22
PCT/US2016/043617 WO2017015582A1 (fr) 2015-07-22 2016-07-22 Procédés permettant de traiter des troubles associés à l'angiogenèse et à une néovascularisation

Publications (1)

Publication Number Publication Date
BR112018001275A2 true BR112018001275A2 (pt) 2018-09-18

Family

ID=57835306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001275A BR112018001275A2 (pt) 2015-07-22 2016-07-22 métodos para tratar transtornos associados à angiogênese e neovascularização

Country Status (11)

Country Link
US (2) US20180207292A1 (fr)
EP (1) EP3324960A4 (fr)
JP (1) JP2018524391A (fr)
KR (1) KR20180034518A (fr)
CN (1) CN108024994A (fr)
AU (1) AU2016297178A1 (fr)
BR (1) BR112018001275A2 (fr)
CA (1) CA2990837A1 (fr)
MX (1) MX2018000869A (fr)
RU (1) RU2018106348A (fr)
WO (1) WO2017015582A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
US20190153119A1 (en) * 2016-04-14 2019-05-23 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with neovascularization
US20190388522A1 (en) * 2017-01-25 2019-12-26 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
AU2018341227A1 (en) * 2017-09-27 2020-04-09 Ohio State Innovation Foundation Tissue factor-targeting CAR-NK and CAR-T cell therapy
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
KR102428619B1 (ko) 2019-09-25 2022-08-04 대구가톨릭대학교산학협력단 망막병증 치료용 약물 방출 콘택트렌즈 및 이의 제조방법
WO2021072265A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
KR20240105241A (ko) 2022-12-27 2024-07-05 주식회사 넥스세라 안구 질환 치료를 위한 효율적인 약물 전달 플랫폼

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
WO2004006962A2 (fr) * 2002-07-12 2004-01-22 Novo Nordisk A/S Compose de liaison au facteur tissulaire
JP2006516564A (ja) * 2003-01-22 2006-07-06 ノボ　ノルディスク　アクティーゼルスカブ Ｔｆ結合薬剤及びそれらの使用
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein
WO2006020979A2 (fr) * 2004-08-13 2006-02-23 Yale University Conjugues du facteur vii permettant de traiter selectivement des troubles de la neovascularisation
WO2007047626A1 (fr) * 2005-10-14 2007-04-26 Alcon, Inc. Traitement de combinaison comprenant de l'acetate d'anecortave et du bevacizumab ou du ranibizumab pour une angiogenese oculaire pathologique
AU2011267106B2 (en) * 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor

Also Published As

Publication number Publication date
AU2016297178A1 (en) 2018-01-25
EP3324960A4 (fr) 2019-01-23
US20210236649A1 (en) 2021-08-05
CN108024994A (zh) 2018-05-11
CA2990837A1 (fr) 2017-01-26
KR20180034518A (ko) 2018-04-04
EP3324960A1 (fr) 2018-05-30
US20180207292A1 (en) 2018-07-26
WO2017015582A1 (fr) 2017-01-26
JP2018524391A (ja) 2018-08-30
MX2018000869A (es) 2018-07-06
RU2018106348A (ru) 2019-08-22

Similar Documents

Publication Publication Date Title
BR112018001275A2 (pt) métodos para tratar transtornos associados à angiogênese e neovascularização
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112018014222A2 (pt) método de tratamento da glomerulopatia c3
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
WO2015117010A3 (fr) Bag3 en tant que cible pour la thérapie de l'insuffisance cardiaque
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
BR112016019432A8 (pt) composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
BR112018067721A2 (pt) anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
EA201691567A1 (ru) Способы лечения легких травм головного мозга
PH12021550872A1 (en) Therapeutic compounds
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112018017240A2 (pt) ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante?
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]